Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSCC_ASCs for Severe Respiratory COVID-19
NCT04341610Phase 2Withdrawn
- Sponsor
- Rigshospitalet
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ASC Group with Placebo Group (2 arms). Primary endpoint: Changes in clinical critical treatment index at 7 days. Planned start Apr 2020; status: withdrawn.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04341610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341610.